Overview Confirmatory Study of DSP-5423P in Patients With Schizophrenia Status: Completed Trial end date: 2018-12-01 Target enrollment: Participant gender: Summary The primary objective of the study is to evaluate the efficacy of DSP-5423P compared with placebo in patients with schizophrenia. Phase: Phase 3 Details Lead Sponsor: Sumitomo Dainippon Pharma Co., Ltd.